Drug intelligence / Profile preview

mgG-2

Development stage: Preclinical
Lead developer: Simplexia
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intranasal, Intramuscular

Overview

mgG-2 is a recombinant protein subunit vaccine candidate being developed by Simplexia for the prevention and treatment of genital herpes caused by Herpes Simplex Virus type 2 (HSV-2). The vaccine targets Glycoprotein G-2 (gG-2), a membrane-associated protein unique to HSV-2 that is involved in immune evasion by acting as a chemokine-binding protein. By utilizing a modified recombinant form of gG-2, the vaccine aims to elicit a specific and robust immune response to prevent viral entry and reduce the frequency of recurrent outbreaks. mgG-2 is currently in preclinical development.

Targets

gG-2 (HSV-2 glycoprotein G)

Beyond the preview

Go deeper on mgG-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mgG-2.

Explore the full profile